Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced parkinson disease and motor fluctuations: The ADVANS study

Archives of Neurology

Volumn 65, Issue 5, 2008, Pages 577-583

  Rascol, Olivier ^a   Poewe, Werner ^c   Lees, Andrew ^d   Aristin, Marina ^a   Salin, Laurence ^b   Juhel, Nolwenn ^b   Waldhauser, Lisa ^e   Schindler, Thomas ^e  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b BOEHRINGER INGELHEIM   (France)

^c Department of Neurology   (Austria)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HYPNOTIC SEDATIVE AGENT; LEVODOPA; NS 2330; PLACEBO; TESOFENSINE;

ADULT; AGED; ARTICLE; CHEST TIGHTNESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HUMAN; INNER EAR DISEASE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; NEUROLOGIC DISEASE; OUTPATIENT CARE; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VERTIGO; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOGENIC MONOAMINES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; PARKINSON DISEASE; PILOT PROJECTS; PLACEBOS; TREATMENT OUTCOME;

EID: 43549099062     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.5.577     Document Type: Article

References (16)

1. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359(9317):1589-1598.
2. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20(5):523-539.
3. Thatte U. NS-2330 (NeuroSearch). Curr Opin Investig Drugs. 2001;2(11):1592-1594.
4. Tesofensine [investigator's brochure]. Ingelheim, Germany: Boehringer Ingelheim GmbH, 2000.
5. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442.
6. Fahn S, Elton R; UPDRS Development Committee. Recent Development in Parkinson's Disease: Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Vol 2. New York, NY: MacMillan Publishing; 1987:153-163.
7. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19(12):1409-1413.
8. Rascol O, Brooks DJ, Melamed E, et al; LARGO (Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily) Study Group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations. Lancet. 2005;365(9463):947-954.
9. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO (Parkinson's Rasagiline: Efficacy and Safety in the Treatment of Off ) study. Arch Neurol. 2005;62(2):241-248.
10. Pearce RKB, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord. 2002;17(5):877-886.
11. Hauser RA, Salin L, Juhel N, Konyago VL; NS 2330 Monotherapy Study Group. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007;22(3):359-365.
12. Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Mov Disord. 2004;19(10):1183-1186.
13. Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol. 2001;24(4):208-213.
14. Nutt JG, Carter JH, Carlson NE. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch Neurol. 2007;64(3):319-323.
15. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord. 1990;5(1):55-59.
16. 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesia. Neurology. 1997;49(3):717-723.